ARTICLE | Company News
Selvita, Menarini deal
March 31, 2017 7:44 PM UTC
Selvita granted Menarini exclusive, worldwide rights to develop and commercialize acute myelogenous leukemia (AML) candidate SEL24. Selvita will receive an upfront payment of €4.8 million ($5.2 millio...